Answers are grounded in this paper and cite their sources.
// Ilaria Laurenzana 1 , Antonella Caivano 1 , Stefania Trino 1 , Luciana De Luca 1 , Francesco La Rocca 1 , Vittorio Simeon 1 , Cristina Tintori 2 , Francesca D’Alessio 3 , Antonella Teramo 4 , Renato Zambello 4 , Antonio Traficante 5 , Maddalena Maietti 5 , Gianpietro Semenzato 4 , Silvia Schenone 6 , Maurizio Botta 2 , Pellegrino Musto 7, * , Luigi Del Vecchio 3, 8, * 1 Laboratory of Preclinical and Translational Research, IRCCS Referral Cancer Center of Basilicata (CROB), Rionero in Vulture (PZ), Italy 2 Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy 3 Biotecnologie Avanzate s.c.a.r.l., CEINGE, Napoli, Italy 4 Department of Medicine Hematology and Clinical Immunology, Padua University School of Medicine, Padova, Italy 5 Unit of Clinical Pathology, IRCCS CROB, Rionero in Vulture (PZ), Italy 6 Department of Pharmacy, University of Genoa, Genova, Italy 7 Scientific Direction, IRCCS CROB, Rionero in Vulture (PZ), Italy 8 Department of Molecular Medicine and Medical Biotechnologies, University of Naples, Napoli, Italy * These authors contributed equally to this work Correspondence to: Ilaria Laurenzana, email: ilaria.laurenzana@crob.it Keywords: natural killer large granular lymphocyte leukemia, Fyn tyrosine kinase, kinase inhibitor, NK cells Received: April 06, 2016 Accepted: August 12, 2016 Published: August 22, 2016 ABSTRACT Natural killer (NK) cell neoplasms are characterized by clonal proliferation of cytotoxic NK cells. Since there is no standard treatment to date, new therapeutic options are needed, especially for NK aggressive tumors. Fyn tyrosine kinase has a key role in different biological processes, such as cell growth and differentiation, being also involved in the pathogenesis of hematologic malignancies. Our previous studies led us to identify 4c pyrazolo[3,4- d ]pyrimidine compound capable of inhibiting Fyn activation and inducing apoptosis in different cancer cell lines. Here we investigated the presence of Fyn and the effect of its inhibitor in NK malignant cells. Firstly, we showed Fyn over-expression in NK leukemic cells compared to peripheral blood mononuclear cells from healthy donors. Subsequently, we demonstrated that 4c treatment reduced cell viability, induced caspase 3-mediate apoptosis and cell cycle arrest in NK cells. Moreover, by inhibiting Fyn phosphorylation, 4c compound reduced Akt and P70 S6 kinase activation and changed the expression of genes involved in cell death and survival in NK cells. Our study demonstrated that Fyn is involved in the pathogenesis of NK leukemia and that it could represent a potential target for this neoplasm. Moreover, we proved that Fyn inhibitor pyrazolo[3,4- d ]pyrimidine compound, could be a started point to develop new therapeutic agents.
No takes yet. Share an insight, caveat, or question.
Laurenzana et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: